Transactivation of EGFR by G protein-coupled receptor in the pathophysiology of intimal hyperplasia

Current Vascular Pharmacology

Volumn 12, Issue 2, 2014, Pages 190-201

  Sur, Swastika ^a   Agrawal, Devendra K ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

A disintegrin and metalloproteinases; Cell proliferation; Epidermal growth factor receptor; G protein coupled receptor; Intimal hyperplasia; Matrix matalloproteinases; Migration; Transactivation

Indexed keywords

ADAM PROTEIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; CATECHOLAMINE; ENDOTHELIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR; G PROTEIN COUPLED RECEPTOR; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; HISTONE DEACETYLASE INHIBITOR; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; THROMBIN; UROKINASE;

ARTERY INTIMA PROLIFERATION; ARTICLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; HUMAN; LIGAND BINDING; PATHOPHYSIOLOGY; PHOSPHORYLATION; SECOND MESSENGER; SIGNAL TRANSDUCTION; TRANSACTIVATION; VASCULAR SMOOTH MUSCLE; ANIMAL; ANTAGONISTS AND INHIBITORS; GENETICS; HYPERPLASIA; INTIMA; PATHOLOGY; PHYSIOLOGY; TRANSCRIPTION INITIATION;

ANIMALS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYPERPLASIA; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; TUNICA INTIMA;

EID: 84900327239     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161112666140226123745     Document Type: Article

References (73)

1. [1] Daub H, Weiss FU, Wallasch C, et al. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 1996; 379: 557-60.
2. [2] Schafer B, Gschwind A, Ullrich A. Multiple G-protein-coupled receptor signals converge on the epidermal growth factor receptor to promote migration and invasion. Oncogene 2004; 23: 991-9.
3. [3] Park YS, Cho NJ. EGFR and PKC are involved in the activation of ERK1/2 and p90 RSK and the subsequent proliferation of SNU-407 colon cancer cells by muscarinic acetylcholine receptors. Mol Cell Biochem 2012; 370: 191-8.
4. [4] Filardo EJ. Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer. J Steroid Biochem Mol Biol 2002; 80: 231-8.
5. [5] Miyamoto S, Hirata M, Yamazaki A, et al. Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Res 2004; 64: 5720-7.
6. [6] Eguchi S, Iwasaki H, Ueno H, et al. Intracellular signaling of angiotensin II-induced p70 S6 kinase phosphorylation at Ser(411) in vascular smooth muscle cells. Possible requirement of epidermal growth factor receptor, Ras, extracellular signal-regulated kinase, and Akt. J Biol Chem 1999; 274: 36843-51.
7. [7] Zhang H, Chalothorn D, Jackson LF, et al. Transactivation of epidermal growth factor receptor mediates catecholamine-induced growth of vascular smooth muscle. Circ Res 2004; 95: 989-97.
8. [8] Zhou W, Ibe BO, Raj JU. Platelet-activating factor induces ovine fetal pulmonary venous smooth muscle cell proliferation: role of epidermal growth factor receptor transactivation. Am J Physiol Heart Circ Physiol 2007; 292: H2773-81.
9. [9] Zhang H, Sunnarborg SW, McNaughton KK, et al. Heparin binding epidermal growth factor-like growth factor signaling in flow-induced arterial remodeling. Circ Res 2008; 102: 1275-85.
10. [10] Huang YL, Shi GY, Lee H, et al. Thrombin induces nestin expression via the transactivation of EGFR signalings in rat vascular smooth muscle cells. Cell Signal 2009; 21: 954-68.
11. [11] Snider AC, Meier KE. Receptor transactivation cascades. Focus on "Effects of alpha1D-adrenergic receptors on shedding of biologically active EGF in freshly isolated lacrimal gland epithelial cells". Am J Physiol Cell Physiol 2007; 292: C1-3.
12. [12] Liebmann C. EGF receptor activation by GPCRs: an universal pathway reveals different versions. Mol Cell Endocrinol 2011; 331: 222-31.
13. [13] Rozengurt E. Mitogenic signaling pathways induced by G protein coupled receptors. J Cell Physiol 2007; 213: 589-602.
14. [14] Chi SS, Vetiska SM, Gill RS, et al. Transactivation of PDGFRbeta by dopamine D4 receptor does not require PDGFRbeta dimerization. Mol Brain 2010; 3: 22.
15. [15] Daub H, Wallasch C, Lankenau A, et al. Signal characteristics of G protein-transactivated EGF receptor. EMBO J 1997; 16: 7032-44.
16. [16] Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37 (Suppl 4): S3-8.
17. [17] Burgess AW. EGFR family: structure physiology signalling and therapeutic targets. Growth Factors 2008; 26: 263-74.
18. [18] Mervine SM, Yost EA, Sabo JL, et al. Analysis of G protein betagamma dimer formation in live cells using multicolor bimolecular fluorescence complementation demonstrates preferences of beta1 for particular gamma subunits. Mol Pharmacol 2006; 70: 194-205.
19. [19] Sato M, Blumer JB, Simon V, et al. Accessory proteins for G proteins: partners in signaling. Annu Rev Pharmacol Toxicol 2006; 46: 151-87.
20. [20] Prossnitz ER, Sklar LA, Oprea TI, et al. GPR30: a novel therapeutic target in estrogen-related disease. Trends Pharmacol Sci 2008; 29: 116-23.
21. [21] Prenzel N, Zwick E, Daub H, et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999; 402: 884-8.
22. [22] Eguchi S, Numaguchi K, Iwasaki H, et al. Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. J Biol Chem 1998; 273: 8890-6.
23. [23] Keely SJ, Calandrella SO, Barrett KE. Carbachol-stimulated transactivation of epidermal growth factor receptor and mitogen-activated protein kinase in T(84) cells is mediated by intracellular ca(2+), PYK-2, and p60(src). J Biol Chem 2000; 275: 12619-25.
24. [24] Andreev J, Galisteo ML, Kranenburg O, et al. Src and Pyk2 mediate G-protein-coupled receptor activation of epidermal growth factor receptor (EGFR) but are not required for coupling to the mitogen-activated protein (MAP) kinase signaling cascade. J Biol Chem 2001; 276: 20130-5.
25. [25] Luttrell LM, Della Rocca GJ, van Biesen T, et al. Gbetagamma subunits mediate Src-dependent phosphorylation of the epidermal growth factor receptor. A scaffold for G protein-coupled receptor-mediated Ras activation. J Biol Chem 1997; 272: 4637-44.
26. [26] Santiskulvong C, Rozengurt E. Protein kinase Calpha mediates feedback inhibition of EGF receptor transactivation induced by Gq-coupled receptor agonists. Cell Signal 2007; 19: 1348-57.
27. [27] Murasawa S, Mori Y, Nozawa Y, et al. Angiotensin II type 1 receptor-induced extracellular signal-regulated protein kinase activation is mediated by Ca2+/calmodulin-dependent transactivation of epidermal growth factor receptor. Circ Res 1998; 82: 1338-48.
28. [28] Stirnweiss J, Valkova C, Ziesche E, et al. Muscarinic M2 receptors mediate transactivation of EGF receptor through Fyn kinase and without matrix metalloproteases. Cell Signal 2006; 18: 1338-49.
29. [29] Luttrell LM, Lefkowitz RJ. The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci 2002; 115: 455-65.
30. [30] Duru EA, Fu Y, Davies MG. Urokinase requires NAD(P)H oxidase to transactivate the epidermal growth factor receptor. Surgery 2012; 152: 879-85.
31. [31] Wetzker R, Bohmer FD. Transactivation joins multiple tracks to the ERK/MAPK cascade. Nat Rev Mol Cell Biol 2003; 4: 651-7.
32. [32] Fan H, Turck CW, Derynck R. Characterization of growth factor induced serine phosphorylation of tumor necrosis factor-alpha converting enzyme and of an alternatively translated polypeptide. J Biol Chem 2003; 278: 18617-27.
33. [33] Ohtsu H, Dempsey PJ, Frank GD, et al. ADAM17 mediates epidermal growth factor receptor transactivation and vascular smooth muscle cell hypertrophy induced by angiotensin II. Arterioscler Thromb Vasc Biol 2006; 26: e133-7.
34. [34] Roelle S, Grosse R, Aigner A, et al. Matrix metalloproteinases 2 and 9 mediate epidermal growth factor receptor transactivation by gonadotropin-releasing hormone. J Biol Chem 2003; 278: 47307-18.
35. [35] Ohtsu H, Dempsey PJ, Eguchi S. ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors. Am J Physiol Cell Physiol 2006; 291: C1-10.
36. [36] Yan Y, Shirakabe K, Werb Z. The metalloprotease Kuzbanian (ADAM10) mediates the transactivation of EGF receptor by G protein-coupled receptors. J Cell Biol 2002; 158: 221-6.
37. [37] Lautrette A, Li S, Alili R, et al. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nat Med 2005; 11: 867-74.
38. [38] Asakura M, Kitakaze M, Takashima S, et al. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med 2002; 8: 35-40.
39. [39] Lucchesi PA, Sabri A, Belmadani S, et al. Involvement of metalloproteinases 2/9 in epidermal growth factor receptor transactivation in pressure-induced myogenic tone in mouse mesenteric resistance arteries. Circulation 2004; 110: 3587-93.
40. [40] Kalmes A, Vesti BR, Daum G, et al. Heparin blockade of thrombin-induced smooth muscle cell migration involves inhibition of epidermal growth factor (EGF) receptor transactivation by heparin-binding EGF-like growth factor. Circ Res 2000; 87: 92-8.
41. [41] Bakken AM, Protack CD, Roztocil E, et al. Cell migration in response to the amino-terminal fragment of urokinase requires epidermal growth factor receptor activation through an ADAM-mediated mechanism. J Vasc Surg 2009; 49: 1296-303.
42. [42] Yang X, Zhu MJ, Sreejayan N, et al. Angiotensin II promotes smooth muscle cell proliferation and migration through release of heparin-binding epidermal growth factor and activation of EGF-receptor pathway. Mol Cells 2005; 20: 263-70.
43. [43] Takaguri A, Kimura K, Hinoki A, et al. A disintegrin and metalloprotease 17 mediates neointimal hyperplasia in vasculature. Hypertension 2011; 57: 841-5.
44. [44] Kim J, Zhang L, Peppel K, et al. Beta-arrestins regulate atherosclerosis and neointimal hyperplasia by controlling smooth muscle cell proliferation and migration. Circ Res 2008; 103: 70-9.
45. [45] Kim J, Ahn S, Rajagopal K, et al. Independent beta-arrestin2 and Gq/protein kinase Czeta pathways for ERK stimulated by angiotensin type 1A receptors in vascular smooth muscle cells converge on transactivation of the epidermal growth factor receptor. J Biol Chem 2009; 284: 11953-62.
46. [46] Hsieh HL, Sun CC, Wang TS, et al. PKC-delta/c-Src-mediated EGF receptor transactivation regulates thrombin-induced COX-2 expression and PGE(2) production in rat vascular smooth muscle cells. Biochim Biophys Acta 2008; 1783: 1563-75.
47. [47] Schauwienold D, Sastre AP, Genzel N, et al. The transactivated epidermal growth factor receptor recruits Pyk2 to regulate Src kinase activity. J Biol Chem 2008; 283: 27748-56.
48. [48] Chansel D, Ciroldi M, Vandermeersch S, et al. Heparin binding EGF is necessary for vasospastic response to endothelin. FASEB J 2006; 20: 1936-8.
49. [49] Santiskulvong C, Rozengurt E. Galardin (GM 6001), a broad-spectrum matrix metalloproteinase inhibitor, blocks bombesin-and LPA-induced EGF receptor transactivation and DNA synthesis in rat-1 cells. Exp Cell Res 2003; 290: 437-46.
50. [50] Ostman A, Bohmer FD. Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatases. Trends Cell Biol 2001; 11: 258-66.
51. [51] Vecchione L, Jacobs B, Normanno N, et al. EGFR-targeted therapy. Exp Cell Res 2011; 317: 2765-71.
52. [52] Levitzki A. EGF receptor as a therapeutic target. Lung Cancer 2003; 41 (Suppl 1): S9-14.
53. [53] Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 2001; 8: 3-9.
54. [54] Yang XD, Jia XC, Corvalan JR, et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001; 38: 17-23.
55. [55] Lynch DH, Yang XD. Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol 2002; 29: 47-50.
56. [56] Hudis CA. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med 2007; 357: 39-51.
57. [57] LaBonte MJ, Wilson PM, Fazzone W, et al. The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models. Cancer Res 2011; 71: 3635-48.
58. [58] Ciardiello F, Tortora G, De Placido S, et al. ZD1839 (Iressa): preclinical studies and pharmacology. Tumori 2002; 88: S155-7.
59. [59] Jones J, Takeda A, Picot J, et al. Lapatinib for the treatment of HER2-overexpressing breast cancer. Health Technol Assess 2009; 13 Suppl 3: 1-6.
60. [60] Aravindan N, Thomas CR, Jr., Aravindan S, et al. Irreversible EGFR inhibitor EKB-569 targets low-LET gamma-radiation-triggered rel orchestration and potentiates cell death in squamous cell carcinoma. PLoS One 2011; 6: e29705.
61. [61] Simon GR, Garrett CR, Olson SC, et al. Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study. Clin Cancer Res 2006; 12: 4645-51.
62. [62] Gonzales PE, Solomon A, Miller AB, et al. Inhibition of the tumor necrosis factor-alpha-converting enzyme by its pro domain. J Biol Chem 2004; 279: 31638-45.
63. [63] Moss ML, Bomar M, Liu Q, et al. The ADAM10 prodomain is a specific inhibitor of ADAM10 proteolytic activity and inhibits cellular shedding events. J Biol Chem 2007; 282: 35712-21.
64. [64] Kveiborg M, Jacobsen J, Lee MH, et al. Selective inhibition of ADAM12 catalytic activity through engineering of tissue inhibitor of metalloproteinase 2 (TIMP-2). Biochem J 2010; 430: 79-86.
65. [65] Rapti M, Atkinson SJ, Lee MH, et al. The isolated N-terminal domains of TIMP-1 and TIMP-3 are insufficient for ADAM10 inhibition. Biochem J 2008; 411: 433-9.
66. [66] Lendeckel U, Kohl J, Arndt M, et al. Increased expression of ADAM family members in human breast cancer and breast cancer cell lines. J Cancer Res Clin Oncol 2005; 131: 41-8.
67. [67] Duffy MJ, Mullooly M, O'Donovan N, et al. The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer? Clin Proteomics 2011; 8: 9.
68. [68] Bendeck MP, Irvin C, Reidy MA. Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Circ Res 1996; 78: 38-43.
69. [69] Erba E, Ronzoni S, Bassano L, et al. The metalloproteinase inhibitor batimastat (BB-94) causes cell cycle phase perturbations in ovarian cancer cells. Ann Oncol 1999; 10: 589-91.
70. [70] Gavras H, Brunner HR, Turini GA, et al. Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man. N Engl J Med 1978; 298: 991-5.
71. [71] Sleight P, Yusuf S, Pogue J, et al. Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet 2001; 358: 2130-1.
72. [72] Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005; 45: 1832-9.
73. [73] Suzuki H, Kanno Y, Sugahara S, et al. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am J Kidney Dis 2008; 52: 501-6.